BIMZELX® (bimekizumab-bkzx) is the first and only IL-17A and IL-17F inhibitor approved for the treatment of adults with moderate to severe plaque psoriasis Approval is supported by three Phase 3 trials where bimekizumab consistently delive...
/PRNewswire/ -- Regulated Information – Inside Information – UCB, a global biopharmaceutical company, announced today that the U.S. Food and Drug...
With three new indications, BIMZELX® (bimekizumab-bkzx) is the first and only IL-17A and IL-17F inhibitor approved in the U.S. for the treatment of four...
Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment, including pricing pressure, political and public scrutiny, customer and prescriber patterns or practices, and the...
ATLANTA,Sept. 30, 2024/PRNewswire/ -- UCB, a global biopharmaceutical company, today announced the start of BE BOLD, a head-to-head Phase 3b study, comparing BIMZELX®(bimekizumab-bkzx), an interleukin (IL)-17A and IL-17F inhibitor, with SKYRIZI®(risankizumab), an IL-23 inhib...
Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment, including pricing pressure, political and public scrutiny, customer and prescriber patterns or practices, ...